Oncolytics Biotech (TSE:ONC) Shares Cross Above Two Hundred Day Moving Average – Time to Sell?

Oncolytics Biotech Inc. (TSE:ONC)’s stock price crossed above its two hundred day moving average during trading on Friday . The stock has a two hundred day moving average of C$8.70 and traded as high as C$14.90. Oncolytics Biotech shares last traded at C$14.90, with a volume of 280 shares traded.

Oncolytics Biotech Stock Performance

The stock’s 50-day simple moving average is C$14.90 and its 200-day simple moving average is C$8.70. The stock has a market cap of C$1.50 billion, a price-to-earnings ratio of -40.27 and a beta of 0.80. The company has a current ratio of 2.99, a quick ratio of 8.86 and a debt-to-equity ratio of 11.75.

Oncolytics Biotech (TSE:ONC) last issued its quarterly earnings results on Wednesday, November 12th. The company reported C($0.14) earnings per share (EPS) for the quarter. Analysts forecast that Oncolytics Biotech Inc. will post -0.41 earnings per share for the current fiscal year.

Oncolytics Biotech Company Profile

Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma.